0001493152-24-007151.txt : 20240220
0001493152-24-007151.hdr.sgml : 20240220
20240220111208
ACCESSION NUMBER: 0001493152-24-007151
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240217
FILED AS OF DATE: 20240220
DATE AS OF CHANGE: 20240220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pershing Edward
CENTRAL INDEX KEY: 0001689739
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36457
FILM NUMBER: 24651491
MAIL ADDRESS:
STREET 1: 2220 SOUTHERLAND AVE
CITY: KNOXVILLE
STATE: TN
ZIP: 37919
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000315545
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 900031917
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 S. GAY STREET
STREET 2: SUITE 1610
CITY: KNOXVILLE
STATE: TN
ZIP: 37929
BUSINESS PHONE: (866) 594-5999
MAIL ADDRESS:
STREET 1: 800 S. GAY STREET
STREET 2: SUITE 1610
CITY: KNOXVILLE
STATE: TN
ZIP: 37929
FORMER COMPANY:
FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020417
FORMER COMPANY:
FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC
DATE OF NAME CHANGE: 20011126
FORMER COMPANY:
FORMER CONFORMED NAME: SPM GROUP INC
DATE OF NAME CHANGE: 19920703
4
1
ownership.xml
X0508
4
2024-02-17
0
0000315545
PROVECTUS BIOPHARMACEUTICALS, INC.
PVCT
0001689739
Pershing Edward
800 S. GAY STREET, SUITE 1610
KNOXVILLE
TN
37929
1
0
0
0
0
8% Unsecured Convertible Promissory Note
2.862
2024-02-17
4
M
0
125000
0
D
2023-02-17
2024-02-17
Series D-1 Convertible Preferred Stock
47180
1535000
D
Series D-1 Convertible Preferred Stock
2024-02-17
4
M
0
47180
0
A
2024-02-17
Common Stock
471800
1008828
D
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note due 2023 (the "2022 Note") at any time while the 2022 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2022 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2022 Note. The 2022 Note was issued pursuant to the Issuer's 2022 Financing.
On February 17, 2024, the 2022 Note was converted into 47,180 shares of Series D-1 Preferred Stock.
/s/ Edward Pershing
2024-02-20